Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Expected to Report Earnings of $ -1.16 per Share
Equity research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) to post earnings of ($ 1.16) per share for the current quarter, according to Zacks investment research. Five analysts have released estimates for Arcturus Therapeutics’ earnings, with the lowest estimate of EPS at ($ 1.29) and the highest estimate at ($ 0.92). Arcturus Therapeutics posted earnings of ($ 0.67) per share in the same quarter last year, which would indicate a negative growth rate of 73.1% year-over-year. The company is expected to publish its next results on Thursday, May 6.
On average, analysts expect Arcturus Therapeutics to report annual earnings of ($ 2.79) per share for the current year, with EPS estimates ranging from ($ 8.11) to $ 3. $ 51. For the next fiscal year, analysts predict the company will post earnings of $ 10.95 per share, with EPS estimates ranging from ($ 4.31) to $ 33.99. Zacks’ BPA averages are an average based on a survey of research analysts who follow Arcturus Therapeutics.
Arcturus Therapeutics (NASDAQ: ARCT) last released its results on Sunday, February 28. The biotech company reported EPS of ($ 1.25) for the quarter, missing the Zacks consensus estimate of ($ 0.88) of ($ 0.37). Arcturus Therapeutics had a negative net margin of 506.70% and a negative return on equity of 52.32%.
Several research analysts recently weighed in on ARCT stocks. B. Riley reduced his price target for Arcturus Therapeutics from $ 45.00 to $ 35.00 and set a “sell” rating for the company in a research note on Monday, March 8. Zacks investment research upgraded Arcturus Therapeutics from a “sell” rating to a “maintain” rating in a research note on Tuesday, March 2. Wells Fargo & Company launched coverage on Arcturus Therapeutics in a research note on Thursday, January 7. They issued an “overweight” rating and a price target of $ 118.00 for the company. Raymond James downgraded Arcturus Therapeutics from an “outperformance” rating to a “market return” rating and set a target price of $ 46.00 for the company. in a report of Tuesday, December 29. Finally, Smith Barney Citigroup raised its price target on Arcturus Therapeutics from $ 62.00 to $ 133.00 in a report on Monday, December 14. Two equity research analysts rated the stock with a sell rating, six assigned a sustaining rating, and four issued a buy rating to the company. The company currently has an average hold rating and a consensus price target of $ 69.31.
Actions of NASDAQ: ARCT open at $ 40.83 on Mondays. Arcturus Therapeutics has a 12 month minimum of $ 11.93 and a 12 month maximum of $ 129.71. The company has a market cap of $ 1.07 billion, a PE ratio of -14.08 and a beta of 3.01. The company has a 50-day moving average of $ 58.67 and a two-hundred-day moving average of $ 62.30. The company has a current ratio of 11.21, a rapid ratio of 11.21 and a debt ratio of 0.06.
In other news from Arcturus Therapeutics, COO Pad Chivukula sold 10,000 shares of the stock in a transaction dated Monday, January 4. The stock was sold for an average price of $ 46.40, for a total value of $ 464,000.00. 12.60% of the shares are held by insiders of the company.
Several hedge funds and other institutional investors have recently changed their holdings in ARCT. Federated Hermes Inc. increased its position in Arcturus Therapeutics shares by 150.8% during the 4th quarter. Federated Hermes Inc. now owns 3,452,810 shares of the biotechnology company valued at $ 149,783,000 after acquiring 2,076,135 additional shares in the last quarter. State Street Corp increased its position in Arcturus Therapeutics shares by 504.7% during the 3rd quarter. State Street Corp now owns 1,560,254 shares of the biotech company valued at $ 66,935,000 after acquiring an additional 1,302,232 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Arcturus Therapeutics by 102.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,422,179 shares of the biotech company valued at $ 61,694,000 after purchasing an additional 718,793 shares during the last quarter. Orbimed Advisors LLC increased its stake in Arcturus Therapeutics by 106.9% in the 4th quarter. Orbimed Advisors LLC now owns 1,280,086 shares of the biotech company valued at $ 55,530,000 after purchasing an additional 661,500 shares in the last quarter. Finally, BlackRock Inc. increased its stake in Arcturus Therapeutics by 53.3% during the 4th quarter. BlackRock Inc. now owns 1,781,955 shares of the biotech company valued at $ 77,301,000 after purchasing an additional 619,727 shares during the last quarter. 74.33% of the shares are currently held by institutional investors and hedge funds.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, an RNA drug company, focuses on the treatment of liver disease and respiratory care. The company engages in the discovery and development of RNA drugs, including the production of RNA drug substance and drug product formulated in nanoparticles; and the development of vaccines against infectious diseases using its RNA autotranscription and replication (STARR) technology.
Read more: Why is insider trading dangerous?
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]